SUPERNUS PHARMACEUTICALS INC (SUPN) Stock News
NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD
SUPN Latest News, Press Relases and Analysis
H.C. Wainwright sees potential competition for Sage from Biogen
H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and its board of directors...
Mentions: SAGE
What Makes Supernus (SUPN) a New Buy Stock
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, but investors are laser-focused on Chair Powell’s language regarding potential rate cuts later this year. Currently, markets are pricing in a roughly 56% chance of a quarter-point cut by September. In the background, rising tensions between Israel and Iran continue to cast a long shadow. Oil prices
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock
Agenus Inc. (NASDAQ:AGEN) is among the 10 Most Undervalued Stocks to Buy for Under $5. Despite a 39% surge over the past month, it is still a bargain stock, considering its low forward price-earnings ratio. The company’s shares have soared on the back of notable recent developments. On June 3, Agenus Inc. (NASDAQ:AGEN) announced that […]
How to get a $40,000 personal loan
Make sure you get the right lender for a $40,000 loan.
Supernus makes depression drug play with $795m Sage buyout
After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space.
Sage, following Setbacks, to sell to Supernus for $561M
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Mentions: SAGE
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading...
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management...
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
Females with ADHD frequently present with inattentive symptoms, which can be more difficult to recognize than the hyperactive and impulsive symptoms more...
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Investors need to pay close attention to Supernus Pharmaceuticals (SUPN) stock based on the movements in the options market lately
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 10.53% and 2.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: AMPH
Supernus Announces First Quarter 2025 Financial Results
Supernus Announces First Quarter 2025 Financial Results
First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI®...